High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients

Kidney International

Volumn 49, Issue 1, 1996, Pages 147-152

  Bostom, Andrew G ^a   Shemin, Douglas ^b   Lapane, Kate L ^b   Hume, Anne L ^b   Yoburn, David ^b   Nadeau, Marie R ^b   Bendich, Adrianne ^b   Selhub, Jacob ^b   Rosenberg, Irwin H ^b  

^a TUFTS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN B GROUP;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030060126     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.19     Document Type: Article

References (44)

1. MAIORCA R, CANCARINI GC, BRUNORI G, CAMERINI C, MANILI L: Morbidity and mortality of CAPD and hemodialysis. Kidney Int 43(Suppl 40):S4-S10, 1993
2. MA KW, GREENE EL, RAIJ L: Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kid Dis 19:505-513, 1992
3. PARFREY PS, HARNETT JD: Long term cardiac morbidity and mortality during dialysis therapy. Adv Nephrol 23:311-339, 1994
4. UELAND PM, REFSUM H, BRATTSTROM LA: Plasma homocystcinc and cardiovascular disease, in Atherosclerotic Cardiovascular Disease. Hemostasis, and Endothelial Function, edited by FRANCIS RBJ, New York, Marcell Dckker Inc., 1992, pp 182-236
5. STAMPFER MJ, MALINOW MR, WILLETT WC, NEWCOMER LM, UPSON B, ULLMAN D: A prospective study of plasma homocyst(e)ine and the risk of myocardial infarction in US physicians. JAMA 268:877-881, 1992
6. ARNESEN E, REFSUM H, BONAA KH, UELAND PM, FORDE OH, NORDREHAUG JE: The Tromso Study: Serum total homocysteine and myocardial infarction, a prospective study. (abstract) Third International Conference on Preventive Cardiology, June 27-July 1, 1993, Oslo, Norway
7. SELHUB J, JACQUES PF, BOSTOM AG, D'AGOSTINO RB, WILSON PW, BELANGER AJ, O'LEARY DH, WOLF PA, SCHAFFER EJ, ROSENBERG IH: Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 332:286-291, 1995
8. WILCKEN DEL, GUPTA VJ: Sulphur-containing amino acids in chronic renal failure with particular reference to cysteine-homocysteine mixed disulfide. Eur J Clin Invest 9:301-307, 1979
9. WILCKEN DEL, GUPTA VJ: Accumulation of sulphur-containing amino acids including cysteine-homocysteine mixed disulfide in patients on hemodialysis. Clin Sci 58:427-431, 1980
10. KANG SS, WONG PWK, BIDANI A, MILANEZ S: Plasma protein-bound homocyst(e)ine in patients requiring chronic hemodialysis. Clin Sci 65:335-337, 1983
11. CHAUVEAU P, CHADEFAUX B, COUDÉ M, AUPETIT J, HANNEDOUCHE T, KAMOUN P, JUNGERS P: Hyperhomocyst(e)inemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43(Suppl 41): S72-S77, 1993
12. HULTBERG B, ANDERSSON A, STERNER G: Plasma homocysteine in renal failure. Clin Nephrol 40:230-234, 1993
13. BOSTOM AG, SHEMIN D, LAPANE KL, MILLER JW, SUTHERLAND P, NADEAU M, SEYOUM E, HARTMAN W, PRIOR R, WILSON PWF, SELHUB J: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case control study. Atherosclerosis 114:93-103, 1995
14. BOSTOM AG, SHEMIN D, LAPANE KL, SUTHERLAND P, NADEAU MR, WILSON PWF, SELHUB J: Excess prevalence of hyperhomocysteinemia in dialysis-dependent end-stage renal disease. (abstract) Irish J Med Sci 164(Suppl 15):3, 1995
15. BRATTSTROM L, ISRAELSSON B, JEPPSSON JO, HULTBERG B: Folic acid-An innocuous means of reducing plasma homocysteine. Scand J Clin Lab Invest 48:215-221, 1988
16. URBINK JB, VERMAAK WJH, VAN DER MERWE A, BECKER PJ: Vitamin 13-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57:47-53, 1993
17. UBBINK JB, HAYWARD WJ, VAN DER MERWE A, BECKER PJ, DELPORT R, POTGIETER HC: Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 124:1927-1933, 1994
18. BRATTSTROM LA, ISRAELSSON B, NORRVING B, BEROOVIST D, THORNE J, HULTBERG B, HAMFELT A: Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis 81:51-60, 1990
19. SELHUB J, MILLER JW: The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosyl-methionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55:131-138, 1991
20. UELAND PM, REFSUM H, STABLER SP, MALINOW MR, ANDERSSON A, ALLEN RH: Total homocysteine in plasma or serum: Methods and applications. Clin Chem 39:1764-1773, 1993
21. ARNADOTTIR M, BRATTSTROM LA, SIMONSEN O, THYSELL H, HULTBERG B, ANDERSSON A, NILSSON-EHLE P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40:236-240, 1993
22. JANSSEN MJ FM, STEHOUWER CDA, VAN DEN BERG M, VAN DER MEULEN J, BOERS GHJ, DONKER AJM: Folic acid lowers elevated homocysteine levels in chronic dialysis patients, (abstract # 86P) J Am Soc Nephrol 4:250, 1993
23. GULDENER C, JANSSEN MJFM, VAN DEN BERG M, STIUWHER CDA, DONKER AJM: Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients. (abstract) Peril Dial Int 14(Suppl 1):S-26, 1994
24. ARAKI A, SAKO Y: Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection. J Chromatogr 422:43-52, 1987
25. SHIN-BUERING Y, RASSHOFER R, ENDRES WA: A new enzymatic method for pyridoxal 5′-phosphate determination. J Inherit Metab Dis 4:123-126, 1981
26. HORNE DW, PATTERSON D: Lactobacillus casei assay of folic acid derivatives in 96-well microtiter plates. Clin Chem 34:2357-2358, 1988
27. SAS: Version 6.08. Cary, N.C., SAS Institute Inc., 1991
28. UELAND PE, REFSUM H: Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy. J Lab Clin Med 114:473-500, 1989
29. BOSTOM AG, BROSNAN JT, HALL B, NADEAU MR, SELHUB J: Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116:59-62, 1995
30. LIVANT EJ, TAMURA T, JOHNSTON KE, VAUGHN WH, BERGMAN SM, FOREHAND J, WALTHAW J: Plasma folate conjugase activites and folate concentrations in patients receiving hemodialysis. J Nutr Biochem 5:504-508, 1994
31. KRUMDIECK CL, ETO I: Folates in tissues and cells. Support for a "two tier" hypothesis of one carbon metabolism, in Chemistry and Biology of Pleridines, edited by COOPER BA, WHITEHEAD MV, Berlin, Walter de Gruyter, 1986, pp 447-466
32. HARKER LA, ROSS R, SLICHTER SJ, SCOTT CR: Homocystine-induced arteriosclerosis. The role of endothelial injury and platelet response in its genesis. J Clin Invest 58:731-741, 1976
33. WALL RT, HARLAN JM, HARKER LA, STRIKER GE: Homocystine-induced endothelial injury in vitro: A model for the study of vascular injury. Thromb Res 18:113-121, 1980
34. HEINECKE JW, ROSEN H, SUZUKI LA, CHAIT A: The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262:10098-10103, 1987
35. DI MINNO G, DAVI G, MRGAGLIONE M, CIRILLO F, GRANDONE F., CIABATTONI G, CATALANO I, STRISCIUOLIO P, ANDRIA G, PATRONO C: Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence efor platelet involvement and probucol-sensitive mechanism. J Clin Invest 92:1400-1406, 1993
36. LENTZ SR, SADLER JE: Inhibition of thrombomodulin surface expression and protein C activitation by the thrombogenic agent homocysteine. J Clin Invest 88:1906-1914, 1991
37. HARPEL PC, CHANG VT, BORTH W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: A potential link betwen thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89:10193-10197, 1992
38. TSAI JC, PERRELLA MA, YOSHIZUMI M, HSIEH CM, HABER E, SCHLEGEL R, LEE ME: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 91:6369-6373, 1994
39. ROLLAND PH, FRIGGI A, BARLATTER A, PIQUET P, LATRILLE V, FAYE MM, GUILLOU J, CHARPIOT P, BODARD H, GHIRINGHELLI O: Hyperhomocysteinemia-induced vascular damage in the mini-pig. Circulation 91:1161-1174, 1995
40. MUDD SH, SKOVBY F, LEVY HL, PETTIGREW KD, WILCKEN B, PYERITZ RE, ANDRIA G, BOERS GH, BROMBERG IL, CERONE R: The natural history of homocystinuria due to cystathionine beta synthase deficiency. Am J Hum Genet 37:1-25, 1985
41. MASSY ZA, CHADEFAUX-VEKEMANS B, CHEVALIER A, BADER CA, DRUEKE TB, LEGENDRE C, LACOUR B, KAMOUN P, KRIS H: Hyperhomocysteinemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 9:1103-1108, 1994
42. O'LEARY DH, POLAK JF, KRONMAL RA, KITTNER SJ, BOND MG, WOLESON SK JR, BOMMER W, PRICE TR, GARDIN JM, SAVAGE PJ: Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke 23:1752-1700, 1992
43. BUTTERWORTH CE, TAMURA T: Folic acid safety and toxicity: A brief review. Am J Clin Nutr 50:353-358, 1989
44. TAKENAKA T, SHIMOMURA T, NAKAYASU H, URAKAMI K, TAKAHASHI K: Effect of folic acid treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Clin Neurol (Jpn) 33:1140-1145, 1993